The U.S. Food and Drug Administration approved the first naloxone nasal spray product available without a prescription.
Similar Posts
FDA Information Session on Generic Drug Research Needs & Opportunities for FY 2026 – 01/21/2026
FDA is hosting a virtual Information Session on Generic Drug Research Needs & Opportunities for fiscal year (FY) 2026 on Wednesday, January 21, 2026.Private Label Skin Care, Inc. – 715880 – 12/18/2025
CGMP/OTC/Adulterated/MisbrandedB. Braun Medical Issues Voluntary Nationwide Recall of Lactated Ringer’s Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL Due to the Presence of Particulate Matter
For Immediate Release – BETHLEHEM, PA – August 19, 2025 – B. Braun Medical Inc. (B. Braun) is voluntarily recalling two lots of Lactated Ringers Injection USP 1000 mL,and 0.9% Sodium Chloride Injection USP 1000 mL to the hospital level due to the presence of particulate matter inside the container.CPG Sec. 130.300 FDA Access to Results of Quality Assurance Program Audits and Inspections
ORA and CDER agree to replace and/or withdraw CPGs in favor of using guidance or procedural documents, as appropriate per GGP regulations.Novel Drug Approvals for 2026
Novel Drug Approvals for 2026FDA In Brief: FDA issues draft guidance to foster oncology product development for pediatric populations
FDA issues draft guidance document, “FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act.” The draft guidance addresses early planning for pediatric evaluation of certain molecularly targeted oncology drugs.